Skip to main content
PharmGen Science, Inc. logo

PharmGen Science, Inc. — Investor Relations & Filings

Ticker · 004720 ISIN · KR7004720009 KO Manufacturing
Open in API
Filings indexed 296 across all filing types
Latest filing 2025-03-11 Proxy Solicitation & In…
Country KR South Korea
Listing KO 004720

About PharmGen Science, Inc.

http://www.pharmgenscience.com/en/

PharmGen Science, Inc. is a pharmaceutical company engaged in the research, development, production, and sale of medicaments. The company's portfolio encompasses a range of prescription (ETC) and over-the-counter (OTC) drugs, including analgesics, antibiotics, and anti-inflammatory agents. A key strategic focus for the company is the discovery and development of novel drugs for gastrointestinal (GI) disorders. PharmGen Science aims to provide integrated pharmaceutical solutions by leveraging its diverse infrastructure and global network.

Recent filings

Filing Released Lang Actions
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by PharmGen Science. It details the date, location, and agenda items for the upcoming Annual General Meeting, including the election of directors and auditors. This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of meeting details and request their participation/votes.
2025-03-11 Korean
주주총회소집공고
AGM Information Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for PharmGen Science. It contains the meeting agenda, details on voting procedures (including electronic voting), and financial summary information (balance sheets and income statements) provided as reference materials for shareholders. This type of document is standard for an AGM and is classified as AGM-R.
2025-03-11 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (Proxy Solicitation & Information Statement) used to solicit votes from shareholders for an upcoming Annual General Meeting. It contains detailed information about the meeting agenda, voting procedures, and financial summaries, fitting the definition of a Proxy Solicitation & Information Statement (PSI).
2025-03-11 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from PharmGen Science regarding a change in sales or profit structure (a preliminary earnings announcement). It provides key financial highlights (revenue, operating profit, net income) for the fiscal year compared to the previous year. It explicitly states that these are preliminary figures subject to audit, which is a standard format for an Earnings Release (ER) in the Korean market (DART system). It is not a full Annual Report (10-K) or a report publication announcement, but rather the initial disclosure of financial performance. FY 2024
2025-02-18 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from PharmGen Science regarding the adjustment of the conversion price for convertible bonds due to a decline in market price. This type of disclosure, which details changes to capital structure instruments like convertible bonds, falls under the 'Capital/Financing Update' category as it relates to financing activities and the terms of debt-to-equity instruments.
2025-02-11 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from PharmGen Science regarding the adjustment of the conversion price for convertible bonds due to a decline in market price. This type of disclosure, which details changes to the terms of existing financial instruments (specifically conversion prices), falls under capital structure and financing updates. In the provided taxonomy, 'CAP' (Capital/Financing Update) is the most appropriate category for adjustments to convertible securities.
2024-12-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.